![Bing Yao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bing Yao
Directeur Général chez
ARRIVENT BIOPHARMA, INC.
Fortune : 19 M $ au 31/07/2026
Profil
Dr. Zheng Bin Yao is an Independent Director at Alumis, Inc. and a Chairman & Chief Executive Officer at Arrivent BioPharma, Inc. He is on the Board of Directors at Alumis, Inc., Immune-Onc Therapeutics, Inc. and NiKang Therapeutics, Inc. Dr. Yao was previously employed as an Independent Non-Executive Director by VISEN Pharmaceuticals, a Chairman, President & Chief Executive Officer by Viela Bio, Inc., an Independent Director by NexImmune, Inc., a Senior Vice President & Head-Immuno-Oncology by MedImmune LLC, a Vice President & Head-Research by Tanox, Inc., a Head-Immuno-Oncology Franchise by AstraZeneca PLC, and a Head-Immunology & Infectious Diseases by Genentech, Inc. He received his graduate degree from Anhui Medical University and a doctorate degree from the University of Iowa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC. 1,32 % | 21/04/2026 | 613 138 ( 1,32 % ) | 18 M $ | 31/07/2026 |
ALUMIS INC. 0,02 % | 30/06/2026 | 27 082 ( 0,02 % ) | 765 067 $ | 31/07/2026 |
Postes actifs de Bing Yao
| Sociétés | Poste | Début |
|---|---|---|
| ALUMIS INC. | Directeur/Membre du Conseil | 01/06/2021 |
| ARRIVENT BIOPHARMA, INC. | Directeur Général | 01/06/2021 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Directeur/Membre du Conseil | 01/04/2019 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Directeur/Membre du Conseil | - |
Anciens postes connus de Bing Yao
| Sociétés | Poste | Fin |
|---|---|---|
| VISEN PHARMACEUTICALS | Directeur/Membre du Conseil | 27/08/2026 |
| NEXIMMUNE, INC. | Directeur/Membre du Conseil | 27/08/2024 |
| VIELA BIO, INC. | Directeur Général | 15/03/2021 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 01/02/2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Corporate Officer/Principal | 19/10/2007 |
Formation de Bing Yao
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
58
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Health Technology |
NexImmune, Inc.
 NexImmune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops T cell immunotherapies | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anhui Medical University
 Anhui Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
